Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Threshold Pharmaceuticals (acquired by Molecular Templates)

2001 FOUNDED
M&A STATUS
61-70 EMPLOYEES
M&A LATEST DEAL TYPE
Description

Developer of drugs and diagnostic agents targeting tumors designed to offer a broad potential to treat a variety of cancers. The company's product candidate portfolio includes evofosfamide to treat pancreatic cancer, glioblastoma, biliary tract cancer, and various solid tumors; and TH-3424 to treat liver cancer, castration-resistant prostate cancer, and T-cell acute lymphoblastic leukemias, enabling medical practitioners to effectively treat cancer.

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Primary Office
  • 170 Harbor Way
  • Suite 300
  • South San Francisco, CA 94080
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Threshold Pharmaceuticals (acquired by Molecular Templates)’s full profile, request a free trial.

Threshold Pharmaceuticals (acquired by Molecular Templates) Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 01-Aug-2017 00000 Completed Profitable
5. PIPE 06-Oct-2009 0000 00000 Completed Profitable
4. PIPE 02-Sep-2008 000.00 00000 Completed Profitable
3. IPO 03-Feb-2005 000.00 0000 00000 Completed Profitable
2. Early Stage VC (Series B) 01-Jan-2004 $41M $49.2M 000.00 Completed Startup
1. Early Stage VC (Series A) 26-Aug-2002 $8.25M $8.25M Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Threshold Pharmaceuticals (acquired by Molecular Templates) Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.00
Series A 0,000,000 00.000000 00 00 00 00 00 00.00
To view this company’s complete Cap Table, request access »

Threshold Pharmaceuticals (acquired by Molecular Templates) Former Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Alta Partners Venture Capital Minority 000 0000 000000 0
CHL Medical Partners Venture Capital Minority 000 0000 000000 0
Federated Kaufmann Fund Mutual Fund Minority 000 0000 000000 0
Frazier Healthcare Partners Venture Capital Minority 000 0000 000000 0
Great Point Partners PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »

Threshold Pharmaceuticals (acquired by Molecular Templates) Executive Team (12)

Name Title Board
Seat
Contact
Info
Harold Selick Ph.D Chief Executive Officer & Board Member
Joel Fernandes Senior Vice President, Finance & Controller
Mark Hopkins Ph.D Vice President, Intellectual Property & Assistant General Counsel
Laura Hansen Ph.D Senior Director, Corporate Communications
Stewart Kroll Senior Vice President, Clinical Operations & Biostatistics

2 Former Executives

You’re viewing 5 of 12 executives. Get the full list »

Threshold Pharmaceuticals (acquired by Molecular Templates) Board Members (9)

Name Representing Role Since Contact
Info
Bruce Cozadd Self Board Member 000 0000
David Hoffmann Ph.D Self Director & Chairman, Audit Committee 000 0000
David Parkinson MD Self Board Member 000 0000
George Parker Ph.D Self Board Member 000 0000
Harold Selick Ph.D Threshold Pharmaceuticals (acquired by Molecular Templates) Chief Executive Officer & Board Member 000 0000

3 Former Board Members

You’re viewing 5 of 9 board members. Get the full list »